Skip to main content
Trending
Ai infrastructureCorporate restructuringDefense procurementAutonomous vehiclesEnterprise aiConsole securityDinosaur evolutionAgentic commerceClinical trialsCorporate mergersDefense policyHealthcare cybersecurityNuclear deterrencePrisoner exchangesProtein designSakharov prizeTargeted oncologyVaccine safetyAbortion rightsAgent monitoringCar-t therapyDefense techEv transitionGlacier dynamicsHardware bansIndustry layoffsRussia-iran relationsSatellite operationsSino-korean relationsSovereign debt

full timeline

Retatrutide Phase 3 clinical trials

Factlen Newsroom· Updated

Follow Retatrutide Phase 3 clinical trials in the Factlen app and get an alert when there is news. Get the app

Illustration: Incretin therapies offer a new pharmacological alternative for sleep apnea patients who struggle to tolerate mechanical airway pressure.From: Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials

Share this story

Latest

On October 24, Eli Lilly announced that its investigational weight-loss drug retatrutide reduced sleep apnea events by up to 34.3 per hour in Phase 3 trials. The results shifted the average trial participant's disease classification from severe down to moderate. In patients without type 2 diabetes, the medication drove up to 22.2 percent body weight loss over 80 weeks.

Earlier in the month, by 07:04 UTC on October 3, Phase 3 trial results showed the drug drove up to 20.8 percent weight loss in patients with type 2 diabetes. The medication suppressed appetite and increased resting energy expenditure, allowing nearly all participants on the highest dose to achieve standard blood sugar control targets, with many normalizing their glucose levels entirely.

How the story developed

On July 11, Eli Lilly reported that its experimental drug retatrutide achieved a 28.3 percent average body weight reduction over 80 weeks in its Phase 3 TRIUMPH-1 trial. The results matched the efficacy of bariatric surgery.

Retatrutide is a first-in-class triple-agonist medication. It targets three distinct metabolic hormones simultaneously: GLP-1, GIP, and glucagon receptors.

Retatrutide significantly reduced the frequency of breathing disruptions in patients without type 2 diabetes.From: Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials ·

By the end of the TRIUMPH-1 trial, over 65 percent of participants receiving the highest dose of the medication reduced their Body Mass Index below the obesity threshold.

The trials also recorded adverse reactions to the treatment. Gastrointestinal side effects resulted in an 11.3 percent discontinuation rate among participants on the highest dose, a rate slightly above that of existing obesity medications.

Patients on the highest dose of retatrutide lost over a fifth of their body weight during the 80-week trial.From: Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials ·

The subsequent trials in diabetic patients demonstrated a magnitude of weight loss that addressed a historical gap, as diabetic patients have historically lost significantly less weight on incretin therapies compared to non-diabetic patients.

What to watch

  • Eli Lilly plans to submit the drug for FDA approval in the first quarter of 2027.

Key numbers

28.3%
Average weight loss at 80 weeks (12mg)
30.3%
Average weight loss at 104 weeks (extension)
45.3%
Participants losing ≥30% of body weight
11.3%
Discontinuation rate due to side effects (12mg)

From: Eli Lilly's Triple-Hormone Agonist Retatrutide Achieves 28% Weight Loss in Phase 3 Trial

Charts, maps and images

The triple-agonist mechanism combines appetite suppression with increased resting energy expenditure.From: Phase 3 Trial Finds Triple-Hormone Agonist Retatrutide Drives 21% Weight Loss in Type 2 Diabetes ·
Retatrutide broke the historical 15% weight loss ceiling for patients with type 2 diabetes.From: Phase 3 Trial Finds Triple-Hormone Agonist Retatrutide Drives 21% Weight Loss in Type 2 Diabetes ·
Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks.From: Eli Lilly's Triple-Hormone Agonist Retatrutide Achieves 28% Weight Loss in Phase 3 Trial ·
For patients with severe obesity who continued treatment for 104 weeks, average weight loss deepened to 30.3%.From: Eli Lilly's Triple-Hormone Agonist Retatrutide Achieves 28% Weight Loss in Phase 3 Trial ·
Unlike earlier medications, retatrutide activates three separate hormone receptors to orchestrate a comprehensive metabolic reset.From: Eli Lilly's Triple-Hormone Agonist Retatrutide Achieves 28% Weight Loss in Phase 3 Trial ·
Illustration: Sleep specialists are increasingly equipped to treat the metabolic drivers of airway collapse.From: Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials ·
Show 1 more
Illustration: Physicians anticipate that triple-hormone therapies could fundamentally alter the standard of care for metabolic disease.From: Phase 3 Trial Finds Triple-Hormone Agonist Retatrutide Drives 21% Weight Loss in Type 2 Diabetes ·

Timeline

October 2026

  1. Triple-Agonist Retatrutide Significantly Reduces Obstructive Sleep Apnea Severity in Phase 3 Trials
  2. Phase 3 Trial Finds Triple-Hormone Agonist Retatrutide Drives 21% Weight Loss in Type 2 Diabetes

July 2026

  1. Eli Lilly's Triple-Hormone Agonist Retatrutide Achieves 28% Weight Loss in Phase 3 Trial